Decay-accelerating factor (DAF) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein that inhibits both the classical and the alternative pathways of complement activation. DAF has been studied extensively in humans under two clinical settings: when absent from the erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH) patients, who suffer from complement-mediated hemolytic anemia, and in transgenic pigs expressing human DAF, which have been developed to help overcome complement-mediated hyperacute rejection in xenotransplantation. Nevertheless, the exact role of DAF in regulating complement activation in vivo on the cell surface and the species specificity of this molecule remain to be fully characterized. To address these issues, we have used gene targeting to produce mice lacking GPI-anchored DAF. We found that erythrocytes from mice deficient in GPI-anchored DAF showed no increase in spontaneous complement activation in vivo but exhibited impaired regulation of zymosan-initiated bystander and antibodytriggered classical pathway complement activation in vitro, resulting in enhanced complement deposition. Despite a high level of C3 fixation, no homologous hemolysis occurred. It is noteworthy that GPI-linked DAF knockout erythrocytes, when tested with human and guinea pig sera, were more susceptible to heterologous complement lysis than were normal erythrocytes. These results suggest that DAF is capable of regulating homologous as well as heterologous complement activation via the alternative or the classical pathway. They also indicate that DAF deficiency alone is not sufficient to cause homologous hemolysis. In contrast, when the assembly of the membrane-attack complex is not properly regulated, as in the case of heterologous complement activation or in PNH patients, impaired erythrocyte DAF activity and enhanced C3 deposition could lead to increased hemolytic reaction.
Complement plays an essential role in host defense (1) . To prevent complement-mediated autologous attack, host tissues express a number of fluid-phase and membrane-bound inhibitors (1, 2) . The activities of the membrane-bound complement inhibitors are generally thought to be species-specific in that under normal circumstances, serum from one species is capable of lysing erythrocytes of another species but not of its own (1, 2) . Decay-accelerating factor (DAF) is a glycosylphosphatidylinositol (GPI)-anchored membrane regulator of complement that inhibits the C3 convertases of both the classical and alternative pathways (3) . DAF acts by facilitating subunit dissociation of preformed C3 convertases and by preventing the assembly of new C3 convertases (4) (5) (6) . The protein originally was purified from human erythrocytes (4) and later was shown to be absent from the blood cells of patients with paroxysmal nocturnal hemoglobinuria (PNH) syndrome, a disease characterized by an increased sensitivity of red blood cells to autologous complement-mediated lysis (7, 8) . It is now understood that the fundamental defect in PNH occurs at the stage of GPI anchor biosynthesis as a result of somatic mutations in the PIG-A gene in hematopoietic stem cells rather than a defect in the DAF gene per se (9) . Thus, DAF and all other GPI-anchored proteins are absent from the affected blood cells of PNH patients (9) .
The in vivo function of DAF in regulating complement activation on the cell surface, highlighted by its absence from the affected erythrocytes of PNH patients, remains an unsettled question. Medof et al. (10) and Wilcox et al. (11) have shown that purified human DAF, when incorporated into PNH erythrocytes in vitro (by virtue of its GPI anchor) could reduce the sensitivity of these cells to complement-mediated lysis. On the other hand, rare cases of specific DAF deficiency in human erythrocytes caused by germ line mutations in the DAF gene have also been identified (Inab phenotype), but individuals with these deficiencies do not develop PNH disease (12) (13) (14) . Also, unlike cells from PNH patients, Inab erythrocytes are not sensitive to acidified serum lysis in vitro (15, 16) . These observations have raised questions about the relevance of DAF deficiency in the pathogenesis of PNH syndrome and have led to the suggestion (17) that the DAF used in the reincorporation study of Medof et al. (10) might have been contaminated with CD59, a second GPI-anchored membrane complement regulator that also is deficient in PNH erythrocytes (9) .
Another clinical setting in which human DAF has been studied intensively is that of xenotransplantation (18) . A major obstacle in xenotransplantation is the hyperacute rejection mediated by human complement (18) . It is generally assumed that activation of human complement on organs from a discordant species is partially a result of a lack of cross-species activity of membrane complement-regulating proteins such as DAF. Consequently, transgenic pigs overexpressing human DAF have been developed with the hope that organs from such animals, when transplanted, will be able to survive acute-phase rejection (18, 19) . Despite the intense interest and research effort devoted to this subject, however, the issue of species specificity of DAF in regulating C3 convertase has not been properly addressed. Earlier studies dealing with this question that used either DAF proteins purified from erythrocytes (4, The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked ''advertisement'' in accordance with 18 U.S.C. §1734 solely to indicate this fact.
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‡ To whom reprint requests should be addressed at: Center for Experimental Therapeutics, University To better define the in vivo function of DAF in regulating complement activation and to further characterize the species specificity of DAF, we have generated mice deficient in the GPI-anchored DAF by using homologous recombination in embryonic stem cells. In the mouse, two DAF genes encoding a GPI-anchored form of DAF (GPI-DAF) and a transmembrane form of DAF (TM-DAF), respectively, have been identified (22, 23) . We chose to target the GPI-DAF gene because both its broad tissue-distribution pattern and the predicted GPI-anchored nature of the protein it encodes suggest that this gene, rather than the TM-DAF gene, is the true murine homolog of human DAF (22, 23) . In this paper, we report the results of our study of GPI-DAF-deficient mouse erythrocytes with regard to their sensitivity to homologous and heterologous complement activation.
MATERIALS AND METHODS
Genomic Clone Isolation. To clone the mouse GPI-DAF gene, the full-length mouse GPI-DAF cDNA was used as a probe to screen a 129͞Sv FixII murine genomic library (Stratagene). This strategy resulted in the isolation and cloning of a 13-kb genomic fragment (Fig. 1A ). The two mouse DAF genes are overall highly homologous but can be distinguished by significant sequence divergence at the 5Ј and 3Ј ends of their cDNAs (22, 23) . Selective sequence analysis of the isolated genomic clone showed it to represent the 5Ј portion of the mouse GPI-DAF gene containing the first four exons (Fig.  1 A) . Exons 2 and 3 were found to encode the first and second short consensus repeats (SCRs) of mouse GPI-DAF (23), respectively.
Generation of GPI-DAF-Deficient Mice. For construction of the targeting vector, a 5-kb BamHI fragment from the 5Ј-f lanking region was subcloned into the unique BamHI site of the vector pPNT (24) . The pPNT vector contains a positive (Neo) and a negative (thymidine kinase) selection marker. After identifying clones containing the 5-kb BamHI fragment in the correct orientation, we ligated a PCR-amplified 1.9-kb XhoI-NotI fragment encompassing exon 4 into the vector at the unique XhoI-NotI sites (Fig. 1 A) . The targeting vector was linearized by using NotI digestion and transfected by using electroporation (30 g of DNA per 8 ϫ 10 6 cells in 0.8 ml of PBS) into TL-1 embryonic stem (ES) cells (a gift from P. Labosky, Department of Cellular and Developmental Biology, University of Pennsylvania). Culturing and electroporation of ES cells were performed according to standard protocols (25, 26) . Transfected ES cells were selected with neomycin (G418, 210 g͞ml) and gancyclovir (2 M). Surviving cell clones were picked into 96 wells, expanded, and screened by Southern blot analysis of genomic DNAs after XbaI digestion with a 300-bp probe (Fig. 1 A) . Additional screening to confirm proper targeting was performed with a Neo probe. Selected ES cell clones were expanded and used for blastocyst microinjection to produce chimeric mice (26) . Confirmation of germ-line transmission of the mutated GPI-DAF gene in chimeric mice and subsequent breeding experiments to produce homozygous mice (F 2 generation) were carried out according to established procedures (26) . The genotypes of the mice were determined by Southern blotting of tail DNA (26) . All ensuing phenotype characterizations were carried out by using mice of the F 2 or F 3 generation that had mixed background (129͞B6).
Northern Blot Detection of GPI-DAF and TM-DAF mRNAs. Total tissue RNAs were extracted with Trizol reagent (GIBCO͞BRL), fractionated in a 1% agarose gel, and transferred to Hybond-N ϩ nylon membranes. To detect GPI-DAF mRNAs, a 276-bp 3Ј cDNA-specific fragment (23) was used as a probe for hybridization in QuickHyb solution (Stratagene). To detect TM-DAF mRNA, the membrane was stripped and rehybridized with a 180-bp specific probe corresponding to the 3Ј cDNA of TM-DAF (23) . Finally, the membrane was stripped again and hybridized with a control probe (glyceraldehyde-3-phosphate dehydrogenase) to confirm equal loading of RNAs.
Isolation of Blood Cells. Blood (10-50 l) was collected from the tail vein of wild-type or knockout mice into either normal saline (for red blood cell analysis) or 1% HCl to lyse and remove erythrocytes (for white blood cell analysis). Cells were harvested, washed with PBS, and counted with a hemocytometer or used for complement deposition or lysis assays.
Fluorescence-Activated Cell Sorter (FACS) Analysis of C3 Deposition. To measure C3 deposition on the erythrocytes, cells (1 ϫ 10 6 to 1 ϫ 10 8 ͞ml in FACS buffer) were incubated for 30 min with an FITC-conjugated polyclonal goat antimouse C3 antibody (Cappel͞ICN), washed, and analyzed by FACScan (Becton Dickinson) by gating of red blood cells in forward and side scatterings. In the first experiment, erythrocytes were analyzed directly to assess the degree of spontaneous complement activation in vivo. In the second experiment, erythrocytes (1 ϫ 10 8 ͞ml) were first coincubated with zymosan particles in normal mouse serum at 37°C for 60 min [in a total volume of 100 l, made by mixing an equal volume of serum and a 50% suspension of zymosan in gelatin-Veronal buffered saline containing 2 mM MgCl 2 and 10 mM EGTA (GVBSEGTA͞Mg 2ϩ )]. The cells and zymosan particles were then washed in FACS buffer, incubated with an FITC-conjugated goat anti-mouse C3 antibody, and analyzed for C3 deposition. Total complement activation by zymosan particles in the fluid phase was determined by analyzing C3 cleavage by using double immunodiffusion electrophoresis. In the third experi- Hemolytic Assays. Hemolytic assays were carried out at 37°C for 30 min by using 2-3 ϫ 10 7 erythrocytes in a 100-l volume containing an appropriate amount of either mouse, human, or guinea pig serum (Sigma). The CH 50 of a serum sample was first determined in a pilot experiment, and appropriate dilution of the serum was made so that 10-60% lysis was expected in the hemolytic assay. At the end of the incubation period, the cells were centrifuged and supernatants were measured spectrophometrically (at 414 nm) to determine hemoglobin release from hemolysis. Percent hemolysis was calculated by dividing the OD 414 value by that of a sample in which total hemolysis was induced by hypotonic shock. Each sample was assayed in duplicate or triplicate. Hemolytic assays were carried out either in GVBS 2ϩ (for classical or classical plus alternative pathways) or GVBS-EGTA͞Mg 2ϩ (for alternative pathway). For total or classical pathway hemolytic assays, erythrocytes were first sensitized with a polyclonal rabbit anti-mouse erythrocyte antibody (1:200, Cappel͞ICN) as described above. For human classical pathway-mediated hemolysis (i.e., no alternative-pathway participation), serum was treated at 50°C for 20 min to inactivate factor B (27) and hence the alternative pathway activity. The effective and selective inactivation of factor B was verified by reconstitution experiments with purified factor B to 400 g͞ml.
RESULTS
Selective Inactivation of the GPI-DAF Gene. Our strategy for targeting the GPI-DAF gene is illustrated in Fig. 1 A. After correct targeting, the first three exons, as well as the intervening intron sequence and a portion of the 5Ј-flanking region, of the GPI-DAF gene were to be deleted and replaced by the Neo gene. No GPI-DAF mRNA was expected to be made, because the proximal promoter sequence necessary for RNA transcription would have been removed. Furthermore, even if alternatively spliced mRNAs and partial GPI-DAF proteins were made, no DAF activity would be displayed by such proteins, because the first two SCRs (encoded by exon 2 and 3, respectively) would be absent. Studies of human DAF have established that SCRs 2, 3, and 4 are essential for the activity of DAF (28) . The successful generation of homozygous GPI-DAF-deficient mice is illustrated in Fig. 1B .
To confirm the inactivation of the GPI-DAF gene, Northern blot analysis was carried out with probes specific for the GPI-DAF and the TM-DAF genes. In prior studies, GPI-DAF, but not TM-DAF was shown to be expressed widely in normal mouse tissues (22, 23) . By using specific cDNA probes, we detected GPI-DAF expression in the lung, liver, intestine, heart, kidney, spleen, uterus, and testis (data not shown). TM-DAF mRNA expression was detected only in mouse testis (ref. 23 ; data not shown). Comparative analysis of wild-type and homozygous knockout mouse tissues confirmed that no GPI-DAF mRNAs were made in the mutant mice ( Fig. 2A) . In contrast to the total abrogation of GPI-DAF gene expression, TM-DAF gene expression in the knockout mouse testis was unaffected (Fig. 2B) . These results indicate that inactivation of the mouse GPI-DAF gene was complete and selective.
The ratio of the three genotypes (wild-type, heterozygous, and homozygous) of the progeny from heterozygous matings showed no significant deviation from the expected 1:2:1 Mendelian distribution (23͞117 were wild type, 67͞117 were heterozygous, 27͞117 were homozygous, 20:57:23). This observation indicates that there was no embryonic lethality associated with GPI-DAF gene inactivation. When housed in a nonspecific pathogen-free facility, GPI-DAF null mice were able to develop, grow, and reproduce, showing no overt abnormal phenotypes.
GPI-DAF-Deficient Erythrocytes Show No Increase in Autologous C3 Deposition in Vivo but Have Increased Bystander
Complement Activation in Vitro. GPI-DAF-deficient mice showed no signs of hemolytic anemia. Total red blood cells and leukocytes were comparable for the wild-type and mutant mice (red blood cells, 9.32 Ϯ 1.06 ϫ 10 9 ͞ml for wild-type and 9.63 Ϯ 1.16 ϫ 10 9 ͞ml for mutant, n ϭ 6; white blood cells, 6.15 Ϯ 1.38 ϫ 10 6 ͞ml for wild-type and 7.71 Ϯ 1.76 ϫ 10 6 ͞ml for mutant, n ϭ 6). FACS analysis showed no spontaneous C3 deposition on the erythrocyte surface of knockout mice (Fig.  3) . To determine whether knockout erythrocytes were more susceptible to C3 fixation from bystander complement activation, cells were coincubated ex vivo in normal mouse serum with zymosan particles, a potent alternative-pathway complement activator (29) . Zymosan-initiated complement activation was confirmed by abundant C3 deposition on the particles and exhaustive C3 cleavage in the serum, as determined by FACScan and double immunodiffusion electrophoresis, respectively (data not shown). Fig. 3 shows that bystander C3 fixation was observed on both the wild-type and the knockout erythrocytes but, on average, C3 deposition was greater on the DAF knockout mouse erythrocytes (P Ͻ 0.001, Student's t test).
GPI-DAF-Deficient Erythrocytes Also Have Impaired Regulation of Autologous Complement Activation via the Classical
Pathway. When wild-type and knockout erythrocytes were first sensitized with a rabbit anti-mouse erythrocyte antibody (1999) and then incubated with normal mouse serum, markedly increased C3 deposition was detected by FACS analysis onto both the wild-type and the knockout cells (Fig. 4) . Again, the level of C3 deposited onto knockout erythrocytes was significantly greater than onto wild-type cells ( Fig. 4 ; P Ͻ 0.001, Student's t test). Despite high amounts of erythrocyte C3 deposition, no lysis of wild-type or GPI-DAF-deficient erythrocytes occurred in this experiment or in the zymosancatalyzed bystander complement activation experiment (Fig. 3) .
GPI-DAF-Deficient Erythrocytes Are More Susceptible than Are Wild-Type Erythrocytes to Heterologous Complement-Mediated Lysis.
To determine whether the activity of mouse GPI-DAF in regulating complement activation on the erythrocyte surface is species-specific, antibody-sensitized wild-type and GPI-DAF-deficient mouse erythrocytes were incubated with normal human or guinea pig serum, and their degree of hemolysis was determined. A significantly greater percentage of GPI-DAF-deficient erythrocytes than wild-type erythrocytes was lysed by both human and guinea pig complement (Fig. 5) . The enhanced susceptibility of GPI-DAFdeficient erythrocytes to heterologous complement lysis was correlated with, and was likely a result of, increased complement activation at the C3 level. When antibody-sensitized wild-type and knockout mouse erythrocytes were incubated with C5-deficient human serum (to prevent lysis) and then analyzed by FACS for C3 deposition, a significantly higher amount of human C3 was deposited onto the knockout erythrocytes than onto the wild-type erythrocytes (mean fluorescence intensity: wild-type, 406 Ϯ 80; knockout, 1250 Ϯ 108; n ϭ 7 mice for each genotype).
We next investigated the effects of mouse GPI-DAF on both the alternative and the classical pathways of human complement activation. For the alternative pathway assay, mouse erythrocytes were incubated with human serum in GVBSEGTA͞Mg 2ϩ buffer. Knockout erythrocytes again displayed an increased sensitivity to lysis, indicating that mouse GPI-DAF is capable of inhibiting the alternative pathway of human complement (Fig. 6A) . To assess the regulatory effect of GPI-DAF on the classical pathway, human serum was heattreated at 50°C for 20 min to inactivate factor B (27) and therefore the alternative-pathway complement activity. The treated serum was confirmed to possess no alternativepathway complement activity (Fig. 6B) . When antibodysensitized mouse erythrocytes were incubated with the factor B-depleted human serum, a pronounced difference was observed between the wild-type and GPI-DAF-deficient erythrocytes in their degrees of lysis (Fig. 6C) . This result suggests that mouse GPI-DAF can regulate rather effectively the human classical pathway of complement.
DISCUSSION
DAF is a GPI-anchored membrane complement regulator that inhibits the C3 and C5 convertases of both the classical and alternative pathways. Reincorporation studies of PNH erythrocytes and purified human DAF have suggested a role for DAF deficiency in the PNH syndrome (10, 11) , yet an absence of hematological disorders in Inab individuals has cast doubt on the relevance of DAF deficiency to complement-mediated hemolysis (12) (13) (14) . Because the Inab genotype is so rare ,   FIG. 3 . GPI-DAF knockout mouse erythrocytes had no spontaneous C3 deposition in vivo but were more susceptible to bystander complement fixation initiated by the alternative pathway complement activator, zymosan (P Ͻ 0.001, Student's t test). Harvested wild-type (WT) or knockout (KO) erythrocytes were either stained directly (no treatment) for C3 or first coincubated in mouse serum with zymosan particles and then stained for C3 deposition. Erythrocytes from 10 animals from each group were analyzed, and values of duplicated experiment were presented. relatively few studies on the sensitivity of Inab erythrocytes to complement activation have been published, and the reported results have not always been consistent (15) (16) (17) 30) . In the present study, we have generated mice deficient in the GPIanchored DAF by homologous recombination in ES cells and have used these mice to evaluate, in a systematic manner, the role of DAF in protecting erythrocytes from C3 deposition and lysis by homologous and heterologous complement.
The lack of increased mouse C3 fixation onto GPI-DAF knockout erythrocytes in vivo suggests that DAF does not play an indispensable role in regulating spontaneous complement activation on the erythrocyte surface. This result seems to be in agreement with the finding of a lack of spontaneous C3 deposition on human Inab erythrocytes (16) . Nevertheless, there are important differences in the expression of complement-regulatory proteins on human and murine erythrocytes (31) . It is known that complement receptor 1 (CR1), which has cofactor activity for factor I and decay-accelerating activity for C3 convertase, is expressed on human but not on murine erythrocytes (32) . On the other hand, the rodent-specific complement-regulatory protein Crry͞p65 is expressed abundantly on mouse erythrocytes (33) . Although we detected no compensatory increase in Crry͞p65 expression on the DAF knockout mouse erythrocytes (data not shown), the constitutive expression of Crry͞p65 may be sufficient to prevent spontaneous complement activation on the erythrocyte surface. The concept that Crry͞p65 is more important in controlling spontaneous complement activation is also supported by the finding that Crry͞p65 knockout resulted in complement-mediated embryonic lethality (34) . Conversely, the increased autologous C3 deposition ex vivo on knockout erythrocytes from bystander and antibody-initiated complement activation ( Fig. 3 and 4) suggests that, under these circumstances, the role of GPI-DAF could not be totally compensated for by other complement-regulatory proteins. It is significant that despite high C3 deposition, no homologous hemolysis resulted.
The notion that the activities of membrane complementregulatory proteins such as DAF are species-restrictive has led to the development of human DAF-transgenic pigs as a strategy for overcoming complement-mediated acute-phase rejection in xenotransplantation (18, 19) . Our observation that mouse GPI-DAF can regulate the activation of human and guinea pig complements suggests that, contrary to what is generally believed, DAF may have significant cross-species activity. Indeed, the degree of inhibition of human classical FIG. 5 . GPI-DAF knockout mouse erythrocytes were more sensitive to heterologous complement lysis. (A) Human complement (Diamedix, Miami; CH50ϭ 205 units/ml, 1:10 or 1:20 dilution; n ϭ 5 for wild-type, n ϭ 4 for knockout mice, P Ͻ 0.005, Student's t test). (B) Guinea pig complement (Sigma; CH50ϭ 147 units/ml, 1:5 dilution; n ϭ 7 for both wild-type and knockout mice, P Ͻ 0.05, Student's t test). Antibody-sensitized mouse erythrocytes were incubated with human or guinea pig serum for 30 min at 37°C, and percent hemolysis was determined by measuring hemoglobin release. Erythrocytes from each mouse were assayed in duplicate.
FIG. 6. Hemolytic assays of wild-type and knockout mouse erythrocytes with human alternative and classical pathway complement. (A) Alternative-pathway assay (n ϭ 6 for both wild-type and knockout mice, duplicate assays for each animal; P Ͻ 0.005, Student's t test). (B) Human serum was heat-treated to inactivate factor B and thus the alternative pathway of complement. Inactivation of factor B was confirmed by alternative-pathway hemolytic assays (using erythrocytes from a wild-type mouse) with or without factor B reconstitution (to 400 g/ml). Values shown are average of duplicate assays. (C) Classical-pathway assay using factor B-depleted serum prepared as shown in B (n ϭ 8 for both wild-type and knockout mice, duplicate assays for each animal; P Ͻ 0.005, Student's t test). A significant difference between wild-type and knockout erythrocytes also was observed in a separate experiment by using factor B-depleted serum obtained from a commercial source (Sigma). For the data presented, fresh human serum from a single donor was used, either directly at 1:20 or 1:10 dilution (A) or heat-treated and used at 1:5 dilution (B and C). Similar results were obtained from experiments using sera from three different donors. (1999) pathway complement activation by mouse GPI-DAF, as revealed by the increased hemolytic response of the knockout erythrocytes (Fig. 6C) , was quite remarkable. This finding raises the possibility that porcine DAF may likewise have a significant regulatory effect on human complement. Porcine DAF has not yet been cloned, and its species specificity remains unknown. However, a recent study on the cloning and expression of pig CD59 cDNA revealed no overt species specificity in the activity of porcine CD59 (35) . Our observation that GPI-DAF-deficient mice are fertile indicates that GPI-DAF is not indispensable for reproduction. This finding is of special interest because studies in humans have shown that DAF is expressed on trophoblasts and sperm cells (36) (37) (38) . DAF has been thought to protect the sperm and the developing fetus from adverse complement-mediated immune reactions (36) (37) (38) . In a previous study, we found that GPI-DAF was selectively up-regulated in the mouse uterus by the female sex hormone estrogen (23) , suggesting a potential role for GPI-DAF in uterine biology. Our current study has shown that DAF is not essential for the female reproductive process. Because the TM-DAF gene is expressed abundantly in the mouse testis and is still intact in the GPI-DAF knockout mice, a role for DAF in testicular biology and͞or sperm function cannot yet be ruled out.
In conclusion, our current study has shown that although DAF deficiency can lead to increased erythrocyte C3 deposition during complement activation, DAF deficiency alone is not sufficient to cause homologous hemolysis. On the other hand, increased lysis of GPI-DAF-deficient erythrocytes by heterologous complements suggests that when the assembly of the membrane-attack complex is not properly regulated (a situation that occurs in PNH syndrome as a result of CD59 deficiency and also that presumably occurs in heterologous complement regulation), DAF deficiency and increased C3 deposition could translate into enhanced hemolytic reaction. The greater sensitivity of GPI-DAF-deficient erythrocytes to classical pathway complement-mediated autologous C3 deposition also suggests that, although Inab individuals do not develop spontaneous intravascular hemolytic anemia, they may be more susceptible to complement receptor-mediated extravascular immune hemolytic disease.
